CONMED Corp — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
CONMED reported Q3 2026 sales of $335.6M (down 0.7% reported, up 6.7% organic constant currency after GI exits). Diluted GAAP EPS was $0.66 (up 613.7% YoY), while adjusted diluted EPS was $1.04 (down 3.2%). Gross margin improved to 56.4% from 49.2%. The company narrowed full-year 2026 guidance: net sales $1,360–$1,366M (vs. prior $1,358–$1,373M), organic constant currency growth 5.0–5.5% (vs. prior 5.0–6.0%), and adjusted diluted EPS $4.54–$4.61 (vs. prior $4.48–$4.60). Domestic sales fell 11% as reported but rose 0.8% organic; international surged 13.8% organic constant currency.
Why this rating
Mixed Q3 beat on adjusted EPS vs. guidance; organic growth solid but domestic weakness offset by international strength. FY guidance tightened modestly, signaling management confidence. At $1.2B market cap, ~$1.36B FY revenue is 113% of size—material but not transformational. GI portfolio exit and operational optimization completed; core business stable.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.